secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117214
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3
--------------------------------------------------------------------------

- Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.
- Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.
- Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.
- R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/0001104659-24-117214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/tm2428175d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer